Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital

RBC Capital lowered the firm’s price target on Crispr Therapeutics to $60 from $66 and keeps a Sector Perform rating on the shares. While RBC “appreciates” all the progress, the firm remains on the sidelines, and remains cautious on Casgevy’s launch as it awaits further progress on the rest of the pipeline, the analyst tells investors in a research note.